NLRP6 as a candidate segmental barrier to carcinogenesis in the human gut - a hypothesis

Sep 22, 2026

Colorectal cancer represents a major global health burden, yet small intestinal cancers are rare within the same gastrointestinal tract. This disparity motivates the hypothesis that segment-specific epithelial programs regulate carcinogenesis. NLRP6 is an inflammasome-forming sensor with established roles in epithelial homeostasis, barrier maintenance, mucosal immune surveillance, and host–microbiota interactions. Using public tissue resources, exploratory reanalysis of single-cell data, and a local colonic cohort, the study proposes NLRP6 varies by segment and context, plausibly contributing to segment-restricted epithelial defense relevant to CRC inflammatory and barrier conditions, pending orthogonal human validation.

LanguageEnglish

CategoryResearch & Report

FormatPDF

Pages8

Reading Time20 min

AccessFree to download

Introduction

Rationale from CRC vs small intestinal cancer disparity

Hypothesis overview and supporting observations

TYPE Hypothesis and Theory PUBLISHED 05 August 2026 DOI 10.3389/fimmu.2026.1823134 OPEN ACCESS EDITED BY Titto Augustine, Purdue University Indianapolis, United States REVIEWED BY Michele Caraglia, University of Campania Luigi Vanvitelli, Italy Palsamy Periyasamy, University of Nebraska Medical Center, United States Shaimaa Hamza, Kazan Federal University, Russia *CORRESPONDENCE Gine´ s Luengo-Gil [gluengo@ucam.edu](gluengo@ucam.edu)[ ](gluengo@ucam.edu)[Ana Tapia-Abell](Ana Tapia-Abell)´an [ana.tapia@um.es](ana.tapia@um.es) †These authors have contributed equally to this work RECEIVED 04 March 2026 REVISED 08 July 2026 ACCEPTED 13 July 2026 PUBLISHED 05 August 2026 CITATION Luengo-Gil G, Arroyo AB, Hurtado-Lo´pez AM, Garca-Solano J, Conesa-Zamora P and Tapia-Abell´an A (2026) NLRP6 as a candidate segmental barrier to carcinogenesis in the human gut: a hypothesis. Front. Immunol. 17:1823134 . doi: 10.3389/fimmu.2026.1823134 COPYRIGHT © 2026 Luengo-Gil, Arroyo, HurtadoLo´pez, Garca-Solano, Conesa-Zamora and Tapia-Abell´an. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. NLRP6 as a candidate segmental barrier to carcinogenesis in the human gut: a hypothesis Gin´es Luengo-Gil 1,2*†, Ana Bel´en Arroyo 1,2, Ana Mar ´ıa Hurtado-Lo´ pez 2, Jos´e Garc ´ıa-Solano 1,2, Pablo Conesa-Zamora 1,2 and Ana Tapia-Abell´an 1,3*† 1Group of Molecular Pathology and Pharmacogenetics, Pathology Department, Instituto Murciano de Investigacio´ n Biosanitaria (IMIB)-Pascual Parrilla, Hospital General Universitario Santa Luca, Cartagena, Spain, 2 Health Sciences Faculty, Universidad Cato´ lica de Murcia (UCAM), Murcia, Spain, 3Group of Immunology, Department of Biochemistry and Molecular Biology (B) and Immunology, Campus de Ciencias de la Salud, Universidad de Murcia, Murcia, Spain Colorectal cancer (CRC) is a major global health burden, whereas small intestinal cancers are rare despite arising within the same gastrointestinal tract. This disparity suggests that segment-speciﬁc epithelial programmes may inﬂuence carcinogenesis. NLRP6 is an inﬂammasome-forming sensor with established roles in epithelial homeostasis, barrier maintenance, mucosal immune surveillance, and host–microbiota interactions. Public human tissue resources, an exploratory reanalysis of currently available single-cell data, and our local colonic cohort, provide hypothesis-generating observations compatible with segmental differences in NLRP6 expression, including very low bulk transcript abundance inhuman colonic samples. However, the currently available human evidence remains limited and heterogeneous, and does not yet support a simple binary model of presence in the small intestine and absence from the colon. Murine studies nevertheless support biological plausibility, as Nlrp6 deﬁciency exacerbates inﬂammation-driven colonic tumourigenesis and impairs epithelial repair. In addition, independent human studies indicate protein-level and clinicopathological relevance of NLRP6 in colonic disease, suggesting that its expression may vary according to segment, cell type, inﬂammatory context, and disease state. We therefore propose that NLRP6 may function as one candidate component of a segment-restricted epithelial defence and mucosal immune surveillance network in the human gut, potentially shaping CRC-relevant inﬂammatory and barrier conditions rather than acting as an established human tumour-suppressive mechanism. This model should now be tested through orthogonal human validation, including protein-based assays, spatial a

FAQs

Why does the paper focus on segment-specific differences between colon and small intestine?

Colorectal cancer is common while small intestinal cancers are rare despite both arising in the gastrointestinal tract, suggesting segment-specific epithelial programs may influence carcinogenesis.

What is NLRP6, according to the document?

NLRP6 is an inflammasome-forming sensor with established roles in epithelial homeostasis, barrier maintenance, mucosal immune surveillance, and host–microbiota interactions.

What types of evidence are used to generate the hypothesis?

The authors use public human tissue resources, exploratory reanalysis of currently available single-cell data, and their local colonic cohort to generate hypothesis-compatible observations about segmental differences in NLRP6 expression.

Sep 22, 2026

Upload by PakDamar76